AI-Designed Bacteriophage Therapy
Pneumonia caused by antibiotic-resistant bacteria
Pre-clinical/ClinicalActive
Key Facts
Indication
Pneumonia caused by antibiotic-resistant bacteria
Phase
Pre-clinical/Clinical
Status
Active
Company
About Locus Biosciences
Locus Biosciences is a private, clinical-stage biotech leveraging a sophisticated AI and robotics platform, LOCUS, to industrialize the development of engineered bacteriophage therapies. The company's most advanced asset, LBP-EC01 for E. coli infections, has reported positive Phase 2 results, positioning it as a leader in the precision antibacterial space. Backed by significant NIH funding and strategic partnerships, Locus is expanding its pipeline to address antibiotic-resistant infections across multiple therapeutic areas while operating its own cGMP manufacturing facility.
View full company profile